





Panel Discussion: Available Treatments and Most Active Target/Payload Combination

Kathleen Moore, MD



Properties of select ADCs in gynecologic oncology



	Mirvetuximab soravtansine ¹⁻³	Tisotumab vedotin ⁴⁻⁶	STRO-002 ^{7,8}
Target	Folate receptor α	Tissue factor (CD142)	Folate receptor α
Linker	Sulfo-SPDB (cleavable)	Valine-citrulline (cleavable)	Valine-citrulline (cleavable)
DAR	3-4	4	4
Payload	DM4	MMAE	SC209 (hemiasterlin)
Class	Maytansinoid	Auristatin analogs	Folate receptor α
Bystander effect	Yes	Yes	Yes
Disease of interest or approved	Ovarian and endometrial cancer	Cervical and ovarian cancer	Ovarian and endometrial cancer

Other antigen targets under clinical investigation include B7-H4, CD166, HER2, mesothelin, MUC16, NOTCH3, PTK7, TROP2^{1, 9-11}

ADC, antibody-drug conjugate; CD, cluster of differentiation; DAR, drug-to-antibody ratio; DM4, maytansinoid DM4; HER2, human epidermal growth factor receptor 2, MMAE, monomethyl auristatin E.

1. Calo CA et al. *Expert Opin Biol Ther.* 2021;21(7):875-887. 2. Manzano A et al. *Cancers (Basel).* 2020;12(8):2223. 3. ClinicalTrials.gov. NCT03832361, NCT04296890, NCT04209855. Accessed September 27, 2022. 4. de Bono JS et al. *Lancet Oncol.* 2019;20(3):383-393. 5. Fu X et al. *Signal Transduct Target Ther.* 2022;7(1):93. 6. ClinicalTrials.gov. NCT03438396, NCT03657043. Accessed Sep 27, 2022. 7. Li X et al. Poster presented at AACR Annual Meeting 2018; Abstract 1782. 8. ClinicalTrials.gov. NCT03748186. Accessed Sep 27, 2022. 9. Hamilton E et al. IGCS Annual meeting 2022. Abstract 1420. 10. Patnaik A et al. ASCO Annual Meeting 2022. Abstract TPS3155. 11. Meric-Berstam F et al. ASCO Annual Meeting 2022. Abstract TPS3153.